이사 / PDMR 지분
풀벡 제약 plc
이사 주식 매입
22 2월 2024 - 풀벡 제약 (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification that on 21 February 2024, Jeremy Skillington, Chief Executive Officer of the Company, purchased 154,764 가격의 보통주 10.8 주당 펜스("매수").
Following the Purchase, Jeremy holds 873,497 ordinary shares representing approximately 0.17 per cent of the Company's issued share capital.
회사는 이 발표에 포함된 정보를 시장 남용 규정(EU) No. 596/2014(영어로 시행됨)("MAR")에 따라 내부 정보로 간주합니다. 규제 정보 서비스(Regulatory Information Service)를 통해 이 발표를 게시함으로써 이 내부 정보는 이제 공개 도메인으로 간주됩니다.
문의
풀벡 제약 Plc CEO 제레미 스킬링턴 Ian O'Connell, CFO
| + 44 (0) 207 183 1499 |
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) 제프 내쉬, 찰리 비슨, 나이젤 버크스, 해리엇 워드(ECM)
| + 44 (0) 207 220 0500 |
싱어캐피털마켓(공동 Broker) 필 데이비스, 샘 버처
| + 44 (0) 207 496 3000 |
J&E 데이비(공동 Broker) 앤서니 파렐, 나일 길크리스트
| + 353 (0) 1 679 6363 |
최적의 전략적 커뮤니케이션 Nick Bastin, Vici Rabbetts, Elena Bates
| + 44 (0) 208 078 4357 |
풀벡 제약회사 소개
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
자세한 정보는 www.poolbegpharma.com 또는 우리를 따라 트위터 및 링크드인 @PoolbegPharma.
미래 예측 진술
이 발표 may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.
관리 책임을 수행하는 사람과 그와 밀접하게 관련된 사람에 의한 거래의 통지 및 공시:
1 | 관리 책임을 다하는 사람 / 연계 인의 내용 | ||
a. | PDMR의 이름 | 제레미 스킬링턴 | |
2 | 통지 이유
| ||
a. | 직위/상태 | 최고 경영자(CEO) | |
b. | 초기 알림/ 개정 | 초기 알림 | |
3 | 발행자, 배출 허용량 시장 참가자, 경매 플랫폼, 경매 인 또는 경매 모니터에 대한 세부 정보 | ||
a. | 성함 | 풀벡 제약 plc | |
b. | 법 | 213800UZ8WJLWYHBFL52 | |
4 | 거래의 세부 사항 : (i) 각 유형의 상품에 대해 반복되는 섹션; (ii) 각 유형의 거래; (iii) 각 날짜; 및 (iv) 거래가 수행 된 각 장소 | ||
a. | 금융 상품 설명, 상품 유형
| 각 £0.002의 보통주
ISIN GB00BKPG7Z60 | |
b. | 거래의 성격 | 보통주 매입 | |
c. | 가격 및 수량 | 물가) | 볼륨 |
10.8p | 154,764 | ||
d. | 집계 된 정보
- 집계 볼륨
-가격 |
위의 4c)와 같이
| |
e. | 거래 날짜 | 21 2월 2024 | |
f. | 거래 장소 | 런던 증권 거래소, AIM 시장(XLON)
|
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.